Introduction
============

Small cell lung cancer (SCLC) accounts for approximately 15% of new lung cancer cases annually. It is a virulent, rapidly growing, early metastasizing, and highly invasive cancer with a 5-year survival rate of \< 7% [@B1], [@B2]. Most of patients with SCLC already have regional or distant spread at diagnosis [@B3]. Despite recent advances in the treatment of SCLC, patient survival only shows a slight improvement [@B4].

Currently, chemotherapy and radiotherapy are the standard treatments for patients with SCLC, and they have provided patients a chance to prolong their survival [@B5]. Surgical treatment is only considered to be limited as an option for early stage SCLC according to recent consensus. The NCCN guidelines version 2 (2018) suggest that patients with SCLC at a stage higher than T1-2 with N0 do not benefit from surgery [@B6]. However, reports show that surgery can significantly improve survival outcomes in SCLC patients and should be considered in the management of SCLC at stages higher than T1-2 with N0 [@B7].

The role of surgery in the multimodality treatment of advanced SCLC remains controversial. Here, we investigated whether patients with stage IIB-IIIC SCLC could benefit from surgical resection as part of the multimodality treatment based on chemotherapy/radiotherapy.

Material and Methods
====================

Data acquisition
----------------

The data of patients with small lung cancer were obtained from the Surveillance, Epidemiology, and End Results (SEER) database (Incidence---SEER 18 Regs Custom Data with additional treatment fields, Nov 2017 Sub, 1973 - 2015 varying) via SEER∗Stat, version 8.3.5 (http://seer. cancer.gov/seerstat/).

The data of patients with SCLC are shown in Figure [1](#F1){ref-type="fig"}A. Briefly, patients with SCLC (ICD-O-3 8041/3, 8043/3, 8044/3, 8045/3) were recruited between 2000 and 2015. The labeled primary sites were limited to C34.1-upper lobe, lung, C34.2-middle lobe, lung, C34.3-lower lobe, lung, and C34.8-Overlapping lesion of lung, C34.9-lung, NOS. The old version of tumor TNM stage was converted to the new AJCC TNM stage manually. The inclusion criteria were as follows: (1) Patients with stage IIB-IIIC disease; and (2) patients treated with chemotherapy or radiotherapy or both. The exclusion criteria were as follows: (1) Patients diagnosed with stage I, IIA, and IV SCLC; (2) patients who did not receive chemotherapy/radiotherapy or surgery; (3) patients who underwent surgical treatment alone. After selection, all patients enrolled in the study were divided into a surgery group and a non-surgery (chemotherapy/radiotherapy) group according to the mode of therapy.

The data of patient and tumor characteristics, including age, sex, race, year of diagnosis, marital status at the time of diagnosis, origin recode NAACCR Hispanic Identification Algorithm (NHIA), primary site, T classification, N classification, TNM stage, surgery recode, chemotherapy recode, radiation recode, survival time, and survival outcomes were derived from the database. Age was categorized as ≤60 years, 6 -70 years, and \>70 years.

Study design
------------

The propensity score matching (PSM) method was used to overcome patient selection bias. The following factors were matched between the two groups: age, sex, race, primary sites, T classification, N classification, TNM stage, marital status at the time of diagnosis, and origin recode NHIA. For each case in the surgery group, three cases in non-surgery group were randomly chosen for pairing by PSM. The non-SCLC cancer-specific survival outcomes were used to perform competing risk analyses.

Statistical analyses were performed using IBM SPSS Statistics 24.0 (IBM, Inc., Armonk, NY) and R version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). Before and after matching, the characteristics between the two groups were compared using chi-square tests. A standardized difference less than 10% was acceptable to evaluate the balance of covariates before and after matching. The overall survival (OS) and the cause-specific survival (CSS) were estimated by the Kaplan-Meier method, and log-rank tests were used to analyze differences between curves. Univariate and multivariate Cox regression analyses were used to identify significant prognostic factors. Two-sided *P* values \< 0.05 were considered statistically significant.

Ethics statements
-----------------

Ethics approval was exempted by the Ethics Committee of Zhongshan Hospital of Fudan University (Shanghai, China), as the SEER is a publicly available database, and data extracted from SEER were identified as nonhuman study.

Results
=======

Patients characteristics
------------------------

There were 85462 patients with SCLC in the SEER database between 2000 and 2015. After rigorous selection, 998 patients with stage IIB-IIIC SCLC who underwent surgery combined with chemotherapy or radiotherapy or both were included in the surgery group, and 17467 patients who only received chemotherapy or radiotherapy or both were included in the non-surgery group. After matching based on propensity scores, 2994 patients were selected and enrolled in the non-surgery group (Figure [1](#F1){ref-type="fig"}A). As shown in Table [1](#T1){ref-type="table"}, compared to the patients who received non-surgical treatment, the patients who received surgery were more likely to be white and married, were more easily to develop tumors located in lower lobe, and had a higher tumor T classification, N classification and TNM stage (all *P* \< 0.05). After matching, there were no significant differences between the two groups in terms of age, sex, race, origin record NHIA**,** marital status, primary sites, TNM stage, T classification, and N classification (all *P* \> 0.05; Figure [1](#F1){ref-type="fig"}B).

Survival analyses
-----------------

The 1, 2, and 3-year OS rates and CSS rates of patents with stage IIB-IIIC SCLC in the two groups were shown in Table [2](#T2){ref-type="table"}. Generally, patients in the surgery group had better OS and CSS rates than those in the non-surgery group (*P* \< 0.001; Figure [2](#F2){ref-type="fig"}A and B). Competing risk model analysis showed that the patients who received non-surgical treatment had a higher risk of cause-specific death from SCLC (*P* \< 0.001), and there was no significant difference in the probabilities of other causes of death (*P* = 0.777; Figure [2](#F2){ref-type="fig"}C).

The correlation between survival and other parameters was further investigated. Univariate analyses showed that age (*P* \< 0.001), sex (*P* \< 0.001), marital status (*P* = 0.009), TNM stage (*P* \< 0.001), T classification (*P* \< 0.001), N classification (*P* \< 0.001), and therapy methods (*P* \< 0.001) were statistically significant predictors of OS (Table [3](#T3){ref-type="table"}). There was no significance in terms of race (*P* = 0.131), origin record NHIA (*P* = 0.941), and tumor primary site (*P* = 0.763). Based on multivariate analyses, age (*P* \< 0.001), sex (*P* \< 0.001), T classification (*P* \< 0.001), N classification (*P* = 0.004), and therapy methods (*P* \< 0.001) were independent prognostic predictors for stage IIB-IIIC SCLC.

To further explore the influence of therapy methods on the survival of stage IIB-IIIC SCLC patients, we stratified the matched patients by significant variables based on multivariate regression model analyses. In patients aged ≤ 60, 60-70, and \>70 years, the survival rates were significantly better in the surgery group than in the non-surgery group (all P \< 0.05; Figure [3](#F3){ref-type="fig"}A-C). Moreover, both male and female patients in the surgery group had better survival than those in the non-surgery group (all *P* \< 0.001; Figure [4](#F4){ref-type="fig"}A and B). In the analysis of tumor T classification, only patients with T3 SCLC had comparable survival outcomes between the surgery group and the non-surgery group (*P* = 0.28), whereas there were significant differences in T1 (*P* = 0.0014), T2 (*P* = 0.036), and T4 (*P* \< 0.001) SCLC (Figure [5](#F5){ref-type="fig"}A-D). With respect to the N classification, surgical treatment was associated with better survival than non-surgical treatment in N0 (*P* = 0.0064), N1 (*P* = 0.001), and N2 (*P* = 0.0022) SCLC, but not in N3 patients (*P* = 0.68; Figure [6](#F6){ref-type="fig"}A-D). For tumor TNM stage, a survival advantage related to surgery was observed in patients with stage IIB (*P* = 0.003) and IIIA (*P* \< 0.001) SCLC (Figure [7](#F7){ref-type="fig"}A and B). However, no significant difference in survival was observed in patients with stage IIIB (*P* = 0.23) and IIIC (*P* = 0.16) SCLC (Figure [7](#F7){ref-type="fig"}C and D).

Discussion
==========

Previously, a large of studies including prospective and retrospective analyses focused on the treatment for NSCLC [@B8]-[@B15], because NSCLC accounted for 85% of lung cancer cases [@B16]. It has been reported that surgery combined with chemotherapy/radiotherapy may improve the survival of the patients with advanced NSCLC [@B9], [@B15]. For SCLC, the standard of care is chemotherapy and radiotherapy, even for limited disease [@B17]. The role of surgery in the treatment of advanced SCLC is controversy [@B18]-[@B20]. Several studies examined the role of surgery in the SCLC patients [@B21]-[@B23], but few studies solved the problem of potential selection biases in the analyses. In the present study, we used the PSM method to eliminate the selection bias by matching factors between the two groups, including age, sex, race, primary sites, T classification, N classification, TNM stage, marital status at the time of diagnosis, and origin record NIHA, and investigated the role of surgery in the chemotherapy/radiotherapy-based multimodality treatment of patients with stage IIB-IIIC SCLC. To our knowledge, it is the first time to use PSM method to eliminate the patient selection bias among the baseline variables of the two groups to investigate the role of surgery in the treatment for advanced SCLC. In addition, we used the competing risk model to distinguish cancer-specific death from death from other causes. No significant difference was found in the probabilities of other causes of death. These processes resulted in a more accurate comparison of survival outcomes between the two groups.

SCLC is a disease with a grave prognosis. In the present study, the 1, 2, and 3-year OS rates of patients with stage IIB-IIIC SCLC were 62.4%, 36.7%%, and 26.7%, respectively, which was consistent with the results of the study by Eberhardt et al. [@B24]. Although surgery offers lung cancer patients the best chance of long-term survival, surgery alone is not sufficient, even for early stage SCLC. Analysis of the National Cancer DataBase indicated that patients with early SCLC who received surgery alone had a lower survival than those who received surgery combined with chemotherapy [@B25]. A retrospective review by Szczesny et al. showed that surgery alone was associated with lower 5-year survival rates than a multidisciplinary approach for very limited disease [@B20]. Furthermore, reports show that chemotherapy/radiotherapy may be effective and could decrease the risk of recurrence in SCLC, and could provide a survival benefit to patients [@B26], [@B27]. However, chemotherapy/radiotherapy alone is associated with poor prognosis when compared with surgery with adjuvant therapy for early stage SCLC [@B28], [@B29]. These results support an increased role of surgery in the multimodality treatment of SCLC, and the combination of surgery with chemotherapy/radiotherapy could be beneficial in patients with early stage SCLC. Increasing evidence indicates that multimodality treatment including surgical resection is associated with better survival than chemotherapy/radiotherapy alone [@B18], [@B30], [@B31]. The treatment, namely surgery combined with adjuvant chemotherapy/radiotherapy, has a 5-year survival of approximately 40% -70% for limited-stage SCLC patients [@B26], [@B32].

In the past, surgery was only recommended for early stage SCLC [@B18], as it has little beneficial effects in patients with advanced disease. However, studies favor surgical intervention in patients with stage III SCLC. Shepherd et al. [@B33] showed that stage II (T1N1, T2N1) and stage III (any T3 or T1-2N2) SCLC patients who underwent surgery and adjuvant chemotherapy had a median survival of 72 weeks and 65 weeks, and projected 5-year survival rates of 24.5% and 24%, respectively. Eberhardt et al. [@B34] showed that the addition of surgery to multimodality treatment provided significant long-term survival, even in locally advanced patients with stage IIB/IIIA SCLC. Tsuchiya et al. [@B32] and Combs et al. [@B23] also reported comparable results. In the present study, OS and CSS were better in patients with stage IIB-IIIC SCLC in the surgery group than in those in non-surgery group, indicating that the inclusion of surgery in the multimodality treatment is beneficial for longer survival**.**

Survival differences stratified by significant variables were analyzed to investigate the impact of therapeutic approaches on the survival of matched patients receiving surgical treatment and non-surgical treatment. The results of multivariate Cox proportional hazards analyses indicated that age, sex, T classification, N classification, and therapy methods were significant independent predictors of survival outcome**.** Generally, elderly patients with SCLC had worse survival probably because they have a significantly higher number of comorbidities, smaller bone marrow reserve, and poor performance status that may affect the tolerance of chemotherapy [@B35], [@B36]. Our results indicated that surgical treatment could be beneficial for patients with stage IIB-IIIC SCLC of all ages compared with non-surgical treatment. With respect to sex, men had higher smoking rates than women at any time point, which may contribute to the higher mortality rate [@B37]. We showed that surgical treatment was associated with significantly better survival than non-surgical treatment for both male and female patients. Matched Kaplan-Meier survival analyses showed that surgery was associated with longer survival for T and N classification SCLC, although the difference was not significant for T3 (*P* = 0.28) and N3 (*P* = 0.68) classifications. The results were consistent with those of a study performed by Wakeam et al. [@B38]. They showed that the survival differences favored surgery in any T classification and both N1 and N2 positive cohorts compared with non-surgical treatment, which indicated that surgery plays an important role in the multimodality treatment of SCLC. In our study, we also did a stratified analysis of survival by TNM stage between the two groups. Consistent with a previous study [@B38], we showed that surgery for stage IIB and IIIA SCLC was associated with improved long-term survival compared with nonsurgical treatment. Moreover, compared with previous studies, we also showed that surgery in the multimodality treatment had no influence on the survival of patients with stage IIIB and IIIC SCLC.

Limitations
===========

The present study had several limitations. First, the information available in the SEER database regarding chemotherapy and radiotherapy for SCLC was limited, and we were unable to obtain specific information regarding chemotherapy drugs, radiotherapy dose, and the treatment course. Second, the tumor differentiation in most cases in the non-surgery group was unknown, and the impact of tumor differentiation on survival outcomes could not be analyzed. Third, certain patients were excluded because of incomplete or inaccurate clinical information, which may lead to potential selection bias.

Conclusions
===========

The present study demonstrated that the combination of surgery with chemotherapy/radiotherapy was associated with better survival outcomes than conventional chemotherapy/radiotherapy alone in stage IIB and IIIA SCLC, but not in stage IIIB and IIIC SCLC. However, surgical resection was not associated with improved survival outcomes in the management of T3 classification and N3 classification.
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###### 

Patient characteristics before and after matching

  Characteristics    Before matching   After matching                              
  ------------------ ----------------- ---------------- ---------- ------- ------- -------
  Age (mean)         66.26             66.74            0.131      67.22   66.74   0.162
  Age group                                             0.019                      0.753
  ≤ 60               4896              239                         702     239     
  60-70              6363              389                         1142    389     
  \> 70              6208              370                         1150    370     
  Sex                                                   0.441                      0.464
  Male               8252              459                         1417    459     
  Female             9215              539                         1577    539     
  Race                                                  0.001                      0.757
  White              15075             902                         2723    902     
  Black              1649              69                          202     69      
  Others             743               27                          69      27      
  NHIA                                                  0.08                       0.165
  SHL                650               48                          114     48      
  NSHL               16817             950                         2880    950     
  Tumor Site                                            \< 0.001                   0.866
  Upper lobe         9928              572                         1726    572     
  Middle lobe        829               55                          141     55      
  Lower lobe         3786              308                         942     308     
  Overlapping        281               22                          70      22      
  Lung, NOS          2643              41                          115     41      
  Marital status                                        0.001                      0.815
  Married            9014              572                         1710    572     
  Ever-married       5820              306                         942     306     
  Never-married      1985              81                          243     81      
  Unknown            648               39                          99      39      
  TNM stage                                             \< 0.001                   1.000
  IIB                1284              388                         1164    388     
  IIIA               6667              470                         1410    470     
  IIIB               7747              131                         393     131     
  IIIC               1769              9                           27      9       
  T classification                                      \< 0.001                   0.934
  T1                 4189              362                         1090    362     
  T2                 2282              241                         723     241     
  T3                 2122              179                         513     179     
  T4                 8874              216                         668     216     
  N classification                                      \< 0.001                   0.235
  N0                 1745              188                         626     188     
  N1                 1600              363                         991     363     
  N2                 11354             422                         1295    422     
  N3                 2768              25                          82      25      

NHIA: NAACCR Hispanic Identification Algorithm

NSHL: Non-Spanish-Hispanic-Latino

SHL: Spanish-Hispanic-Latino

###### 

The survival rate in non-surgery group and surgery group

  Survival rate   Total   Non-surgery group   Surgery group
  --------------- ------- ------------------- ---------------
  1-year OS       62.4%   60.6%               67.8%
  1-year CSS      66.9%   65.4%               71.5%
  2-year OS       36.7%   35.1%               41.5%
  2-year CSS      42.1%   40.4%               46.8%
  3-year OS       26.7%   24.8%               32.6%
  3-year CSS      32.2%   30.1%               38.0%

OS: overall survival

CSS: cause-specific survival

###### 

Univariate and multivariate analyses of overall survival of all patients after matching

  Variables          Univariate Analysis   Multivariate analysis                                        
  ------------------ --------------------- ----------------------- ---------- ----------- ------------- ----------
  Age                                                              \< 0.001                             \< 0.001
  ≤ 60               Reference             Reference                          Reference   Reference     
  60 - 70            1.370                 1.247-1.506             \< 0.001   1.369       1.245-1.506   \< 0.001
  \> 70              1.850                 1.684-2.033             \< 0.001   1.865       1.694-2.053   \< 0.001
  Sex                                                                                                   
  Male               Reference             Reference                          Reference   Reference     
  Female             0.835                 0.779-0.896             \< 0.001   0.818       0.760-0.880   \< 0.001
  Race                                                             0.131                                
  White              Reference             Reference                                                    
  Black              0.896                 0.778-1.031             0.126                                
  Others             0.849                 0.672-1.072             0.169                                
  NHIA                                                                                                  
  SHL                Reference             Reference                                                    
  NSHL               0.933                 0.831-1.187             0.941                                
  Tumor Site                                                       0.763                                
  Upper lobe         Reference             Reference                                                    
  Middle lobe        1.017                 0.866-1.195             0.835                                
  Lower lobe         1.044                 0.962-1.132             0.302                                
  Overlapping        1.107                 0.829-1.479             0.491                                
  Lung, NOS          0.975                 0.859-1.106             0.689                                
  Marital status                                                   0.009                                0.115
  Married            Reference             Reference                          Reference   Reference     
  Ever-married       1.107                 1.025-1.196             0.010      1.105       1.019-1.200   0.016
  Never-married      0.894                 0.780-1.024             0.105      1.028       0.896-1.179   0.698
  Unknown            0.985                 0.808-1.202             0.885      1.079       0.884-1.317   0.454
  TNM stage                                                        \< 0.001                             
  IIB                Reference             Reference                                                    
  IIIA               1.206                 1.117-1.302             \< 0.001                             
  IIIB               1.540                 1.380-1.717             \< 0.001                             
  IIIC               1.898                 1.321-2.728             \< 0.001                             
  T classification                                                 \< 0.001                             \<0.001
  T1                 Reference             Reference                          Reference   Reference     
  T2                 1.135                 1.036-1.244             0.007      1.112       1.015-1.219   0.023
  T3                 0.946                 0.851-1.051             0.299      1.134       0.986-1.291   0.058
  T4                 1.227                 1.119-1.346             \< 0.001   1.360       1.226-1.509   \< 0.001
  N classification                                                 \< 0.001                             \< 0.001
  N0                 Reference             Reference                          Reference   Reference     
  N1                 1.027                 0.930-1.135             0.596      1.207       1.064-1.370   0.004
  N2                 1.245                 1.133-1.369             \< 0.001   1.461       1.295-1.647   \< 0.001
  N3                 1.966                 1.582-2.444             \< 0.001   2.134       1.697-2.685   \<0.001
  Therapy                                                                                               
  Non-surgery        Reference             Reference                          Reference   Reference     
  Surgery            0.809                 0.746-0.878             \< 0.001   0.807       0.744-0.876   \< 0.001
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